Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer

References

• Bellezza G, Cavaliere A, Sidoni A (2009) IMP3 expression in non-small cell lung cancer. Hum. Pathol. 40: 1205–1206.
   PubMedGoogle Scholar
• Findeis-Hosey JJ, Xu H (2011) The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum. Pathol. 42: 303–314.
   PubMedGoogle Scholar
• Findeis-Hosey JJ, Yang Q, McMahon LA, Spaulding BO, Li F, Xu H (2010) IMP3: an immunohistochemical marker for invasive squamous cell carcinoma and its high-grade precursor lesions of the lung. Mod. Pathol. 23: 402A.
   Google Scholar
• Findeis-Hosey JJ, Yang Q, McMahon LA, Spaulding BO, Li F, Xu H (2010) Usefulness of EZH2 and IMP3 in discriminating high grade neuroendocrine carcinoma from carcinoids in small biopsies and fine needle aspiration specimens of the lung. Mod. Pathol. 23: 401A.
   Google Scholar
• Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H (2010) IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum. Pathol. 41: 477–484.
   PubMed Web of Science ®Google Scholar
• Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED (2008) External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112: 1471–1479.
   PubMedGoogle Scholar
• Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48: 1118–1127.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL, Wu CL (2008) Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin. Cancer Res. 14: 5579–5584.
   PubMedGoogle Scholar
• Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 7: 556–564.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL, Kwon ED (2008) Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112: 2676–2682.
   PubMedGoogle Scholar
• Liao B, Hu Y, Herrick DJ, Brewer G (2005) The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem. 280: 18517–18524.
   PubMed Web of Science ®Google Scholar
• Mohanty SK, Lu DI, Dresser K, Jiang Z (2008) An oncofetal protein, IMP3: a novel biomarker to predict tumor progression in the low grade Ta urothelial carcinoma of the bladder. Mod. Pathol. 21: 171A.
   Google Scholar
• Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM (1997) Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14: 2729–2733.
   PubMedGoogle Scholar
• Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knochel W, Adler G, Gress TM (1999) Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. 88: 95–99.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Christiansen J, Lykke-Andersen J, Johnson AH, Wewer UM, Nielsen FC (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell Biol. 19: 1262–1270.
   PubMed Web of Science ®Google Scholar
• Schaeffer DF, Owen D, Lim HJ, Mehl E, Buczkowski AK, Chung SW, Scudamore CH, Owen DA, Ng SSW, Huntsman DG (2009) Insulin-like growth factor-2 mRNA binding protein 3 (IGF2BP3) expression may be a marker for an unfavorable prognosis in pancreatic ductal adenocarcinoma. Mod. Pathol. 22: 321A.
   Google Scholar
• Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z (2008) IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin. Cancer Res. 14: 1701–1706.
   PubMedGoogle Scholar
• Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, Nielsen FC (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 25: 1456–1468.
   PubMed Web of Science ®Google Scholar
• Vohra P, Cagle PT, Allen TC, Dresser K, Chakraborty S, Fraire AE (2008) Tissue microarray study of RNA-binding protein IMP3 in primary non-small cell lung cancers: prediction of survival in early stage squamous cell carcinomas. Mod. Pathol. 21: 352A.
   Google Scholar
• Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Banger C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG (2003) L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br. J. Cancer 88: 887–894.
   PubMedGoogle Scholar
• Xu H, Bourne PA, Spaulding BO, Wang HL (2007) High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum. Pathol. 38: 555–563.
   PubMedGoogle Scholar
• Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K (2005) KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am. J. Surg. Pathol. 29: 188–195.
   PubMedGoogle Scholar